NCT04457050View on ClinicalTrials.gov

Effect of Hepatitis C Clearance on Insulin Resistance

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

November 1, 2019

Study Completion Date

December 30, 2019

Conditions
Insulin ResistanceHepatitis C
Interventions
DRUG

Sofosbuvir 400 milligram

single daily dose of 400 milligrams

DRUG

Daclatasvir 60 milligram

single daily dose of 60 milligrams for 12 weeks

DRUG

Ribavirin 400 milligram

weight based dose, 1200 mg for weight \> 75 kilogram, and 1000 milligram if weight \< 75 kilograms for 12 weeks

DRUG

Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab

single daily dose for 12 weeks

Trial Locations (1)

21521

Faculty of Medicine, Alexandria

All Listed Sponsors
lead

Alexandria University

OTHER

NCT04457050 - Effect of Hepatitis C Clearance on Insulin Resistance | Biotech Hunter | Biotech Hunter